Casdin Capital LLC Has $38.78 Million Stake in Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Casdin Capital LLC lowered its stake in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBTGet Rating) by 31.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,325,000 shares of the company’s stock after selling 600,000 shares during the period. Global Blood Therapeutics makes up approximately 1.1% of Casdin Capital LLC’s portfolio, making the stock its 28th biggest holding. Casdin Capital LLC’s holdings in Global Blood Therapeutics were worth $38,783,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in shares of Global Blood Therapeutics by 1.7% during the 3rd quarter. Janus Henderson Group PLC now owns 6,272,682 shares of the company’s stock worth $159,826,000 after buying an additional 104,532 shares in the last quarter. Perceptive Advisors LLC lifted its position in shares of Global Blood Therapeutics by 6.1% during the 3rd quarter. Perceptive Advisors LLC now owns 4,407,399 shares of the company’s stock worth $112,300,000 after buying an additional 254,710 shares in the last quarter. Polar Capital Holdings Plc lifted its position in shares of Global Blood Therapeutics by 54.8% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,160,900 shares of the company’s stock worth $29,580,000 after buying an additional 410,900 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Global Blood Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 1,074,035 shares of the company’s stock worth $31,437,000 after buying an additional 11,430 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Global Blood Therapeutics by 16.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 776,157 shares of the company’s stock worth $19,776,000 after buying an additional 110,167 shares in the last quarter.

Several research firms have commented on GBT. StockNews.com raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. Morgan Stanley lifted their price target on shares of Global Blood Therapeutics from $28.00 to $31.00 and gave the stock an “equal weight” rating in a report on Monday, February 28th. Oppenheimer lowered their price target on shares of Global Blood Therapeutics from $86.00 to $71.00 in a report on Thursday, May 5th. Cowen lowered their price target on shares of Global Blood Therapeutics from $72.00 to $67.00 in a report on Thursday, February 24th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Global Blood Therapeutics in a report on Monday, March 28th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Global Blood Therapeutics has a consensus rating of “Buy” and an average price target of $55.42.

Global Blood Therapeutics stock traded up $0.28 during mid-day trading on Thursday, reaching $25.51. The company’s stock had a trading volume of 18,678 shares, compared to its average volume of 1,226,416. Global Blood Therapeutics, Inc. has a 12-month low of $22.67 and a 12-month high of $41.73. The company has a market capitalization of $1.66 billion, a P/E ratio of -5.18 and a beta of 1.09. The company has a debt-to-equity ratio of 4.34, a quick ratio of 7.74 and a current ratio of 8.52. The firm’s fifty day moving average price is $31.84 and its two-hundred day moving average price is $30.42.

Global Blood Therapeutics (NASDAQ:GBTGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The business had revenue of $55.20 million during the quarter, compared to analyst estimates of $56.13 million. Global Blood Therapeutics had a negative net margin of 146.82% and a negative return on equity of 129.74%. Global Blood Therapeutics’s revenue was up 41.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.21) EPS. On average, research analysts predict that Global Blood Therapeutics, Inc. will post -4.64 EPS for the current fiscal year.

About Global Blood Therapeutics (Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

Read More

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBTGet Rating).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.